Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
Odontol. sanmarquina (Impr.) ; 24(2): 13-18, abr.-jun. 2021.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1178062

RESUMEN

Objetivo. El objetivo de este estudio fue cuantificar la liberación de flavonoides y flúor en probetas de ionómero vítreo convencional tipo II modificado con extracto de propóleo. Métodos. Fueron utilizadas 60 unidades de análisis. El extracto etanólico de propóleo al 2% fue incorporado a un ionómero vítreo tipo II. Para la determinación de la liberación de flavonoides el laboratorio analizó la concentración de quercetina por ml de solución, sea agua destilada o solución fisiológica durante un periodo de 5 días. Resultados. Hubo liberación inicial de 0,40 mg/ml de flúor en solución fisiológica y de 0,35 mg/ml de flúor en agua destilada, y una liberación final de 0 mg/ml de flavonoides y de flúor en solución fisiológica y de 0,18 mg/ml de flúor en solución de agua destilada. Conclusiones. La liberación de flúor y flavonoides se produce en mayor concentración en las primeras horas, decreciendo a medida que pasan las horas.


Objective. The objective of this study was to quantify the release of flavonoids and fluoride in test tubes of conventional type II vitreous ionomer modified with propolis extract. Methods. Sixty units of analysis were used. The 2% propolis ethanolic extract was incor- porated into a type II glass ionomer. To determine the release of flavonoids, the laboratory analyzed the concentration of quercetin per ml of solution, either distilled water or physiological solution, during a period of 5 days. Results. There was an initial release of 0.40 mg/ml of fluorine in physiological solution and 0.35 mg / ml of fluorine in distilled water, and a final release of 0 mg/ml of flavonoids and fluorine in physiological solution and of 0,18 mg/ml of fluorine in distilled water solution. Conclusions. The release of fluoride and flavonoids occurs in greater concentration in the first hours, decreasing as the hours go by.

2.
Neurología (Barc., Ed. impr.) ; 34(1): 1-6, ene.-feb. 2019. tab, graf
Artículo en Español | IBECS | ID: ibc-177272

RESUMEN

Introducción: La comorbilidad psiquiátrica es común en epilepsia, de ahí la importancia de considerar en qué medida los fármacos antiepilépticos pueden influir en el estado de ánimo. El objetivo de este trabajo es analizar el efecto de lacosamida en la calidad de vida y en la conducta del paciente epiléptico en la práctica clínica. Métodos: Estudio multicéntrico, observacional y prospectivo en pacientes diagnosticados de epilepsia, mal controlados que recibieron tratamiento adyuvante con lacosamida. Mediante 4 visitas durante 12 meses se valoró el impacto del fármaco en la calidad de vida y el estado de ánimo utilizando el cuestionario de calidad de vida QOLIE-10, la escala hospitalaria de ansiedad y depresión (HADS) y la escala de impulsividad de Barratt (BIS-11), además se determinó su eficacia y seguridad. Resultados: Se incluyeron 55 pacientes, edad media 47,1 ± 18,4 años; porcentaje inicial de comorbilidad psiquiátrica 34,5% y número medio de crisis/mes previo 3,6 ± 4,3. Las escalas QOLIE-10 y HADS reflejaron mejoras estadísticamente significativas en pacientes que partían de una situación basal desfavorable (ansiedad, depresión y/o baja calidad de vida). La escala BIS-11 no detectó la aparición de conductas impulsivas durante el seguimiento. Tras 12 meses de tratamiento el 51,9% de los pacientes estuvo sin crisis, y un 77,8% presentó una educción ≥ 50%. La mayoría de efectos adversos fueron leves, obligando a retirar el fármaco en 10 casos (18,2%). Conclusiones: Lacosamida ofrece un perfil de eficacia y seguridad favorable, y podría constituir una opción terapéutica útil en pacientes con epilepsia y comorbilidad psiquiátrica


Introduction: Psychiatric comorbidities are common in epileptic patients, and evaluating the impact of antiepileptic drugs on patients’ moods is therefore essential. The aim of this study is to assess the effects of lacosamide on behaviour and quality of life in people with epilepsy. Methods: We conducted a multicentre prospective observational study of poorly-controlled epileptic patients who received lacosamide as an adjuvant treatment. Patients were evaluated on 4 occasions during a 12-month period. The impact of lacosamide on patients’ mood and quality of life was assessed with the Quality of Life in Epilepsy Inventory-10 (QOLIE-10), the Hospital Anxiety and Depression Scale (HADS), and the Barratt Impulsiveness Scale (BIS-11). As a secondary objective, we evaluated the effectiveness and safety of lacosamide. Results: We included 55 patients with a mean age of 47.1 ± 18.4 years. At baseline, 34.5% of the patients had psychiatric comorbidities; the mean number of crises in the previous month was 3.6 ± 4.3. The QOLIE-10 and HADS scales revealed statistically significant improvements in patients with a poor baseline condition (anxiety, depression, and/or poor quality of life). The BIS-11 scale detected no impulsive behaviour during follow-up. After 12 months of treatment, 51.9% of the patients were seizure-free and 77.8% experienced a reduction of at least 50% in seizure frequency. Adverse effects were mild in most cases; lacosamide was discontinued in 10 patients (18.2%)


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anticonvulsivantes/uso terapéutico , Trastornos de Ansiedad/psicología , Depresión/psicología , Epilepsia/tratamiento farmacológico , Quimioterapia Combinada , Epilepsia/psicología , Estudios Prospectivos , Escalas de Valoración Psiquiátrica Breve , Calidad de Vida , Resultado del Tratamiento
3.
Harmful Algae ; 81: 77-85, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30638501

RESUMEN

The ability of cyanobacteria to produce toxins and other secondary metabolites is patchily distributed in natural populations, enabling the use of cellular oligopeptide compositions as markers to classify strains into ecologically-relevant chemotypical subpopulations. The composition and spatiotemporal distribution of Microcystis chemotypes within and among waterbodies was studied at different time scales by analyzing (i) Microcystis strains isolated between 1998 and 2007 from different Spanish reservoirs and (ii) individual Microcystis aeruginosa colonies collected from pelagic and littoral habitats in Valmayor reservoir (Spain) during a bloom. No agreement between chemotypes and both morphotypes and genotypes (based on cpcBA-IGS, 16S-23S rRNA ITS and mcyB genes) was found, suggesting that oligopeptide profiles in individual strains evolve independently across morphospecies and phylogenetic genotypes, and that the diversity of microcystin variants produced cannot be explained by mcyB gene variations alone. The presence of identical chemotypes in spatially-distant reservoirs with dissimilar trophic state, lithology or depth indicate that waterbody characteristics and geographical boundaries weakly affect chemotype composition and distribution. At smaller spatiotemporal scales (i.e. during bloom), M. aeruginosa populations showed high number of chemotypes, as well as marked differences in chemotype composition and relative abundance among the littoral and pelagic habitats. This indicates that the factors influencing chemotype composition, relative abundance and dynamics operate at short spatial and temporal scales, and supports emerging hypotheses about interactions with antagonistic microorganisms as possible drivers for widespread chemical polymorphisms in cyanobacteria.


Asunto(s)
Microcystis , Variación Genética , Oligopéptidos , Filogenia , España , Encuestas y Cuestionarios
4.
Neurologia (Engl Ed) ; 34(1): 1-6, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-27993420

RESUMEN

INTRODUCTION: Psychiatric comorbidities are common in epileptic patients, and evaluating the impact of antiepileptic drugs on patients' moods is therefore essential. The aim of this study is to assess the effects of lacosamide on behaviour and quality of life in people with epilepsy. METHODS: We conducted a multicentre prospective observational study of poorly-controlled epileptic patients who received lacosamide as an adjuvant treatment. Patients were evaluated on 4 occasions during a 12-month period. The impact of lacosamide on patients' mood and quality of life was assessed with the Quality of Life in Epilepsy Inventory-10 (QOLIE-10), the Hospital Anxiety and Depression Scale (HADS), and the Barratt Impulsiveness Scale (BIS-11). As a secondary objective, we evaluated the effectiveness and safety of lacosamide. RESULTS: We included 55 patients with a mean age of 47.1±18.4 years. At baseline, 34.5% of the patients had psychiatric comorbidities; the mean number of crises in the previous month was 3.6±4.3. The QOLIE-10 and HADS scales revealed statistically significant improvements in patients with a poor baseline condition (anxiety, depression, and/or poor quality of life). The BIS-11 scale detected no impulsive behaviour during follow-up. After 12 months of treatment, 51.9% of the patients were seizure-free and 77.8% experienced a reduction of at least 50% in seizure frequency. Adverse effects were mild in most cases; lacosamide was discontinued in 10 patients (18.2%). CONCLUSIONS: Lacosamide is a safe and effective treatment option for patients with epilepsy and psychiatric comorbidities.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Lacosamida/uso terapéutico , Adulto , Ansiedad/psicología , Depresión/psicología , Quimioterapia Combinada , Epilepsia/psicología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Escalas de Valoración Psiquiátrica , Calidad de Vida , Resultado del Tratamiento
6.
Rev. argent. dermatol ; 97(4): 6-18, dic. 2016. ilus, tab
Artículo en Español | LILACS | ID: biblio-843098

RESUMEN

Se comunican cinco pacientes con mastocitosis cutánea, en la forma clínica de "telangiectasia macularis eruptiva perstans" (TMEP), con hallazgos clínicos asociados. En la mayoría de los pacientes, la enfermedad se presenta en adultos con manifestaciones clínicas limitadas a la piel, con buen pronóstico. Destacamos la importancia de su conocimiento por el dermatólogo, la necesidad de su estudio y seguimiento multidisciplinario.


Five patients with cutaneous mastocytosis are presented with the clinical variant of "macularis eruptive telangiectasia perstans" (METP), with associated clinical findings. In most cases the disease occurs in adults with clinical manifestations limited to the skin with a good prognosis. We emphasize the importance of studying by a dermatologist and the necessity of interdisciplinary consideration and a proper follow-up.

8.
Rev. chil. dermatol ; 27(2): 212-217, 2011. ilus
Artículo en Español | LILACS | ID: lil-645032

RESUMEN

La Aplasia Cutis Congénita, es un grupo heterogéneo de alteraciones que consisten en la falta congénita localizada o extensa, de piel, que puede acompañarse de ausencia de estructuras subyacentes. Su apariencia clínica es variable y su origen es multifactorial. Presentamos el caso de un recién nacido con Aplasia Cutis Congénita, sin antecedentes familiares de esta enfermedad ni historia de uso materno de drogas, en quien no se constataron hallazgos extracutáneos.


Congenital aplasia cutis, is a heterogeneous group of disorders that involve the congenital absence, localized or extensive, of the skin, which may be accompanied by the absence of underlying structures. Its clinical appareance is variable with a multifactorial origin. We report the case of a newborn with Congenital Aplasia Cutis with no family history of the disease or history of maternal drug abuse, in whom extracutaneous findings were not found.


Asunto(s)
Humanos , Masculino , Recién Nacido , Displasia Ectodérmica/diagnóstico , Biopsia , Cráneo , Diagnóstico Diferencial , Ecocardiografía , Ecoencefalografía , Piel/patología
11.
J Clin Microbiol ; 47(6): 1918-9, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19386840

RESUMEN

Nocardia takedensis is a recently described species isolated from soil. The first clinical isolate in Japan has recently been reported. This report describes the first clinical isolate of N. takedensis in Spain from a respiratory specimen.


Asunto(s)
Nocardiosis/diagnóstico , Nocardia/aislamiento & purificación , Infecciones del Sistema Respiratorio/microbiología , Adulto , ADN Bacteriano/química , ADN Bacteriano/genética , ADN Ribosómico/química , ADN Ribosómico/genética , Complicaciones de la Diabetes , Granuloma Eosinófilo/complicaciones , Femenino , Humanos , Nocardiosis/microbiología , ARN Ribosómico 16S/genética , Análisis de Secuencia de ADN , España
14.
Int J Tuberc Lung Dis ; 11(10): 1080-6, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17945064

RESUMEN

OBJECTIVE: To evaluate changes in the molecular epidemiology of tuberculosis (TB) in Zaragoza, Spain, over a decade that has seen large social and health changes, including the attenuation of the human immunodeficiency virus (HIV) epidemic and increased immigration. DESIGN: A population-based molecular study was conducted using standard restriction fragment length polymorphism IS6110 typing that included all patients with bacteriologically confirmed TB living in the Zaragoza area from 2001 to 2004. The current situation was compared with that described in a previous study from 1993 to 1995. RESULTS: A total of 454 Mycobacterium tuberculosis isolates were genotyped; 239 (52.6%) were grouped in 45 clusters composed of 2 to 85 isolates. Independent risk factors for clustering were identified. The main differences with the previous study were the increase of TB cases among immigrants, a decrease in HIV-TB co-infected patients and the occurrence of a large TB outbreak involving 85 patients (M. tuberculosis Zaragoza [MTZ] strain). CONCLUSION: A change in the epidemiological pattern of TB has been observed in the last years. TB transmission is more common among the Spanish-born population, while foreign birth is significantly less associated with clustering. A single epidemic strain caused 18.7% of all TB cases.


Asunto(s)
ADN Bacteriano/genética , Transmisión de Enfermedad Infecciosa , Mycobacterium tuberculosis/genética , Polimorfismo de Longitud del Fragmento de Restricción , Tuberculosis/transmisión , Adulto , Análisis por Conglomerados , Dermatoglifia del ADN , Brotes de Enfermedades/estadística & datos numéricos , Femenino , Genotipo , Humanos , Incidencia , Masculino , Mycobacterium tuberculosis/aislamiento & purificación , Estudios Retrospectivos , Factores de Riesgo , España/epidemiología , Tuberculosis/epidemiología , Tuberculosis/microbiología
16.
Orthod Craniofac Res ; 8(2): 106-13, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15888123

RESUMEN

In these studies, a rat model of orthodontic tooth movement was used to support the premise that periodontal ligament (PDL) cells experience plasma membrane disruption and resealing events upon application of mechanical stress. Immunoelectron microscopy, showed albumin in the cytoplasm of PDL and bone lining cells in the tension side of moved molars. The intracellular localization of this large molecule (60 KDa) suggests that these cells have undergone plasma membrane disruption and resealing. To further assess these and previous findings, fluorescent dyes (FITC-dextran and rhodamine-dextran) were delivered into the vascular system followed by application of 50 g of static load. These large dextran molecules (10 KDa) were preferentially taken up by PDL cells of the buccal (tension side) of moved molars. These cells were determined to be viable since dead cells do not retain these diffusible tracers. These studies provide evidence of a novel cellular mechanism for uptake and release of molecules and suggest a potential role for plasma membrane disruption in the mechanotransduction of orthodontic tooth movement.


Asunto(s)
Membrana Celular/ultraestructura , Fluoresceína-5-Isotiocianato/análogos & derivados , Ligamento Periodontal/citología , Técnicas de Movimiento Dental , Animales , Membrana Celular/fisiología , Supervivencia Celular/fisiología , Citoplasma/fisiología , Citoplasma/ultraestructura , Dextranos , Femenino , Fibroblastos/fisiología , Fibroblastos/ultraestructura , Colorantes Fluorescentes , Mecanotransducción Celular/fisiología , Microscopía Fluorescente , Microscopía Inmunoelectrónica , Modelos Animales , Diente Molar , Ligamento Periodontal/fisiología , Ratas , Ratas Sprague-Dawley , Rodaminas , Albúmina Sérica/análisis , Estrés Mecánico
18.
J Clin Microbiol ; 43(3): 1220-7, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15750087

RESUMEN

We used spoligotyping and restriction fragment length polymorphism (RFLP) of the IS6110-insertion sequence to study the molecular epidemiology of multidrug-resistant (MDR) tuberculosis in Spain. We analyzed 180 Mycobacterium tuberculosis complex isolates collected between January 1998 and December 2000. Consecutive isolates from the same patients (n = 23) always had identical genotypes, meaning that no cases of reinfection occurred. A total of 105 isolates (58.3%) had unique RFLP patterns, whereas 75 isolates (41.7%) were in 20 different RFLP clusters. Characterization of the katG and rpoB genes showed that 14 strains included in the RFLP clusters did not actually cluster. Only 33.8% of the strains isolated were suggestive of MDR transmission, a frequency lower than that for susceptible strains in Spain (46.6%). We found that the Beijing/W genotype, which is prevalent worldwide, was significantly associated with immigrants. The 22 isolates in the largest cluster corresponded to the Mycobacterium bovis strain responsible for two nosocomial MDR outbreaks in Spain.


Asunto(s)
Farmacorresistencia Bacteriana Múltiple , Mycobacterium tuberculosis/genética , Adulto , Proteínas Bacterianas/genética , Catalasa/genética , ARN Polimerasas Dirigidas por ADN/genética , Femenino , Genotipo , Humanos , Masculino , Mycobacterium tuberculosis/clasificación , Mycobacterium tuberculosis/efectos de los fármacos , Polimorfismo de Longitud del Fragmento de Restricción
20.
Eur J Clin Microbiol Infect Dis ; 23(7): 567-9, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15257445

RESUMEN

Reported here are two cases of Mycobacterium malmoense lymphadenitis that occurred in two immunocompetent children in Spain. To the best of our knowledge, these are the first documented cases of extrapulmonary infection by M. malmoense in Spain. This report serves to draw attention to this emerging nontuberculous mycobacterium that is gaining increasing recognition as a pulmonary and extrapulmonary pathogen in different countries.


Asunto(s)
Inmunocompetencia , Linfadenitis/microbiología , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Micobacterias no Tuberculosas/aislamiento & purificación , Antituberculosos/administración & dosificación , Niño , Preescolar , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Escisión del Ganglio Linfático/métodos , Linfadenitis/diagnóstico , Linfadenitis/inmunología , Linfadenitis/terapia , Masculino , Infecciones por Mycobacterium no Tuberculosas/inmunología , Infecciones por Mycobacterium no Tuberculosas/terapia , Medición de Riesgo , Índice de Severidad de la Enfermedad , España , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA